{Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis}

Citation:

Kastritis, E., Kostopoulos, I. V., Terpos, E., Paiva, B., Fotiou, D., Gavriatopoulou, M., Kanellias, N., et al. (2018). {Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis}. Blood Cancer Journal, 8, 46. presented at the may, Springer US. Copy at http://www.tinyurl.com/yxp4vtqh